Upstream / Downstream
Explore pathways related to this product.
CST Antibody Performance Guarantee
To Purchase # 8902SC
|8902SC||10 µg (With Carrier)||$179.00|
|8902SF||10 µg (Carrier Free)||$179.00|
|8902LC||50 µg (With Carrier)||$529.00|
|8902LF||50 µg (Carrier Free)||$529.00|
|$ 0. 00|
Find answers on our FAQs page.
PTM information and tools available.
Human Tumor Necrosis Factor-α (hTNF-α) #8902
The purity of recombinant hTNF-α was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hTNF-α and staining overnight with Coomassie Blue.Learn more about how we got this image
The viability of L-929 cells treated with increasing amounts of hTNF-α in the presence of 2 ng/ml actinomycin D was determined. Cells were stained with crystal violet at the end of treatment and the OD595 was determined.Learn more about how we got this image
Gallery: Human Tumor Necrosis Factor-α (hTNF-α) #8902
- The purity of recombinant hTNF-α was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hTNF-α and staining overnight with Coomassie Blue.
- The viability of L-929 cells treated with increasing amounts of hTNF-α in the presence of 2 ng/ml actinomycin D was determined. Cells were stained with crystal violet at the end of treatment and the OD595 was determined.
- Western blot analysis of extracts from HeLa cells treated with hTNF-α for 20 minutes, using Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb #3033 (upper) and total NF-κB p65 Antibody #3034 (lower).
Recombinant human TNF-α (hTNF-α) Val77-Leu233 (Accession #HUMTNFAB) was produced in E. coli at Cell Signaling Technology.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTNF-α. All lots are greater than 98% pure.Molecular Formula:
Recombinant hTNF-α does not have a Met on the amino terminus and has a calculated MW of 17,352. DTT-reduced and non-reduced protein migrate as 18 kDa polypeptides. The expected amino-terminal VRSSS of recombinant hTNF-α was verified by amino acid sequencing. TNF-α is a non-disulfide-linked homotrimer in solution as determined by chemical cross-linking.Bioactivity:
The bioactivity of hTNF-α was determined in an L-929 cell viability assay. The ED50 of each lot is between 10-100 pg/ml.Endotoxin:
Less than 0.01 ng endotoxin/1 μg hTNF-α.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hTNF-α. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
TNF-α, the prototypical member of the TNF protein superfamily, is a homotrimeric type-II membrane protein (1,2). Membrane bound TNF-α is cleaved by the metalloprotease TACE/ADAM17 to generate a soluble homotrimer (2). Both membrane and soluble forms of TNF-α are biologically active. TNF-α is produced by a variety of immune cells including T cells, B cells, NK cells and macrophages (1). Cellular response to TNF-α is mediated through interaction with receptors TNF-R1 and TNF-R2 and results in activation of pathways that favor both cell survival and apoptosis depending on the cell type and biological context. Activation of kinase pathways (including JNK, ERK (p44/42), p38 MAPK and NF-κB) promotes the survival of cells, while TNF-α mediated activation of caspase-8 leads to programmed cell death (1,2). TNF-α plays a key regulatory role in inflammation and host defense against bacterial infection, notably Mycobacterium tuberculosis (3). The role of TNF-α in autoimmunity is underscored by blocking TNF-α action to treat rheumatoid arthritis and Crohn’s disease (1,2,4).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.